These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27116231)

  • 1. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up.
    Elaraoud I; Quhill H; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):105-9. PubMed ID: 27116231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema.
    Elaraoud I; Attawan A; Quhill F
    Ophthalmol Ther; 2016 Jun; 5(1):95-104. PubMed ID: 26885863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
    McCluskey JD; Kaufman PL; Wynne K; Lewis G
    Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
    [No Abstract]   [Full Text] [Related]  

  • 4. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
    Currie CJ; Holden SE; Berni E; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 7. The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.
    Eaton A; Koh SS; Jimenez J; Riemann CD
    Ophthalmol Ther; 2019 Mar; 8(1):51-62. PubMed ID: 30560505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
    Schmit-Eilenberger VK
    Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema.
    Singh P; Chedid A; Deuchler SK; Kohnen T; Müller M; Koch FH
    Int Med Case Rep J; 2018; 11():265-269. PubMed ID: 30410411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluocinolone acetonide 0.19 mg intravitreal implant improves foveal thickness and reduces treatment burden for up to 1 year in eyes with persistent diabetic macular edema.
    Coney JM
    Int Med Case Rep J; 2019; 12():161-169. PubMed ID: 31213929
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
    Holden SE; Currie CJ; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK.
    Mushtaq B; Bhatnagar A; Palmer H
    Clin Ophthalmol; 2021; 15():2935-2943. PubMed ID: 34262254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
    Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
    Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema.
    Holden SE; Habib M; Currie CJ
    Curr Med Res Opin; 2020 Jun; 36(6):959-965. PubMed ID: 32267790
    [No Abstract]   [Full Text] [Related]  

  • 17. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
    Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
    Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
    Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
    Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
    Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
    Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN
    Pessoa B; Melo-Beirão J; Meireles A; Menéres P
    Int Med Case Rep J; 2020; 13():437-448. PubMed ID: 32982484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.